Further exploratory analysis indicated CD4_Tfh_CXCL13 cells as an important predictive biomarker for NAIC, which may help identify patients who are most likely to benefit from the treatment regimen. The gene discussed is CXCL13; the disease is hereditary North American Indian childhood cirrhosis.